Backlog Data

Showing 1797 articles
Business

Commerzbank's Meteoric Rise: Is There Still Value Left for Investors?

Following a staggering 92.9% one-year surge, Commerzbank shares have cooled slightly. With the stock now trading around €34.69, analysts are divided: deep-value models signal significant upside, while traditional metrics suggest a fair price. We examine the data and the debate shaping one of Germany's banking turnaround stories.

Business

NextEra Bets Big on Tech's Power Hunger: Nuclear, Renewables, and Carbon Capture in Focus

NextEra Energy is aggressively pursuing long-term power supply agreements with major technology firms, positioning itself as a one-stop shop for clean, reliable electricity to fuel the data center boom. Its strategy hinges on a three-pronged approach: record renewable energy additions, potential nuclear fleet expansion, and a pioneering gas plant with carbon capture technology developed with ExxonMobil.

Business

Idorsia's Latin American Gambit: QUVIVIQ Deal with EMS Signals Strategic Shift Amid Pipeline Scrutiny

Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.